SUMMARY During an eight year period, 32 patients with definite or suspected multiple sclerosis (MS) were seen with paroxysmal neurological disturbances, which included tonic seizures, paroxysmal dysarthria, paraesthesiae and pain in the limbs, as well as trigeminal neuralgia. In 21 of these patients the paroxysmal disorders were treated with carbamazepine, and in six the effect was compared with placebo. In the majority carbamazepine was effective in controlling the paroxysmal symptoms. Side-effects were troublesome in a few patients, but they could usually tolerate small doses, which still gave relief. Although the patho-physiological basis for these paroxysmal disorders remains unexplained, their response to carbamazepine suggests a common mechanism.
A variety of fleeting neurological symptoms are experienced by patients with multiple sclerosis (MS). Not uncommonly these are provoked by a hot bath, smoking, exertion, or flexion of the spine (McAlpine, Lumsden, and Acheson, 1965) . Distinct from these are stereotyped disturbances recurring repeatedly in brief paroxysms. Such manifestations include tonic seizures, paroxysmal dysarthria, paraesthesiae and pain in the limbs, and trigeminal neuralgia. The similarity of trigeminal neuralgia to the other paroxysmal disturbances has been referred to previously (Espir, Watkins, and Smith, 1966; Espir and Walker, 1967) . The paroxysms may each last from a few seconds to a minute or so, recurring several times an hour, apparently spontaneously but sometimes precipitated by various stresses. These bouts usually remit and may be forgotten if they occur early in the disease, or are overshadowed later by more permanent disability; for this reason their incidence has probably been underestimated. The value of carbamazepine in the treatment of trigeminal neuralgia, whether or not it is associated with MS, is now generally accepted, and evidence is accumulating that it also controls other types of paroxysmal disturbances in MS. We wish to report here our experience with carbamazepine in the treatment of such disturbances, including a comparison with placebo in six patients. ' Present address: Regional Department of Neurosurgery and Neurology, Derbyshire Royal Infirmary, Derby.
PATIENTS AND METHOD
Among approximately 600 patients with undoubted or suspected MS seen by one of us (M.L.E.E.) in Leicester between 1960 and 1968, 32 are known to have had paroxysmal disorders. This should not be regarded as the exact incidence, as earlier patients were not specifically asked about such symptoms. During the last four years, 21 of these patients have been treated with carbamazepine and the results reviewed (see Table) . In six patients the effects of carbamazepine and placebo were compared. The regime for each preparation was I tablet four times daily for one day and then a whole tablet four times daily for not less than three days. The drug and identical dummy tablets were thus provided successively on a random basis by the hospital pharmacist and only he knew the order in which they were administered until both had been taken for an equal period (a tablet of carbamazepine = 200 mg). PAROXYSMAL DYSARTHRIA Eight patients with paroxysmal dysarthria have been seen. Six were reported previously by Espir et al. (1966) , and two of these (cases nos. 5 and 6) were treated successfully with carbamazepine; subsequently both have had further relapses typical of MS. Another patient with MS and paroxysmal dysarthria which responded dramatically to carbamazepine was the subject of an additional communication (Espir and Walker, 1967) .
We have also seen a further patient who has had two bouts of paroxysmal dysarthria, and with the second of these it was possible to compare the effects of carbamazepine and placebo. CASE 3 A woman, aged 27, had her first symptons of MS in September 1962. These consisted of frequent transient attacks of vertigo and tingling in the left arm, which stopped after about two months. In December 1962 she complained of transient episodes of numbness of the right side of the face and right arm with slurred speech, lasting for less than a minute at a time, but recurring approximately every half hour. The significance of these attacks was not appreciated at the time. She was treated with a compound tablet containing ergotamine tartrate and phenobarbitone (Bellergal) and then with prochlorperazine without benefit, but the attacks ceased after about three months. In November 1967 brief paroxysms of dysarthria, with numbness of her left upper lip and ataxia, recurred up to 10 times each day. During a week on placebo, attacks continued with the same frequency. After two doses of carbamazepine the attacks stopped, but treatment was discontinued four days later because of side-effects. The paroxysmal dysarthria recurred and was then controlled by 50 mg carbamazepine four times daily, which she continued for three months. Since this time she has remained free from paroxysmal disturbances, despite increasing disability from spastic paraparesis with sensory impairment in both legs.
PAROXYSMAL PARAESTHESIAE Three patients with probable MS have been seen with repetitive stereotyped sensory disturbances affecting the limbs. They were all improved by small doses of carbamazepine though in two side-effects were prominent. Placebo and carbamazepine were compared in one of these patients.
CASE 4 A factory worker, aged 51, had a two year history of difficulty in walking due to stiffness and dragging of his left leg. He also complained of a burning sensation in this limb, coming in bouts lasting three to four seconds, recurring as often as every 20 minutes but with varying frequency over the two year period. During the last year his right hand had become weak with numbness of the third, fourth, and fifth fingers and he had paraesthesiae in both legs. Examination revealed a spastic tetraparesis with wasting and weakness of small muscles of the left hand without sensory loss. Investigations including plain radiographs of the spine, myelography, and CSF examination were negative. Placebo administered during a four day period when he was having frequent paroxysms of the burning sensation in the left leg afforded no relief. After the first day of treatment with carbamazepine, the paroxysms became infrequent and they ceased within four days. Treatment was then discontinued because of lightheadedness and ataxia, whereupon the paroxysms returned. They were subsequently controlled satisfactorily by 150 mg carbamazepine daily which he has taken for 18 months. The other two patients in this group were women with advanced MS. They gained only partial relief from carbamazepine and could not tolerate more than 400 mg daily.
TRIGEMINAL NEURALGIA This well-recognized complication was seen in nine patients with MS and these are included for comparison with the other groups of paroxysmal disorders. The mean age of this group was higher (see Table) . One patient was not treated. Four were initially treated with phenytoin, two with relief. One of these however relapsed and, after a temporary response to carbamazepine, subsequently required an alcohol block. The remaining four patients were successfully treated with carbamazepine; one relapsed later and had an alcohol injection.
DISCUSSION
Despite the increasing recognition of these paroxysmal disturbances in MS during recent years, their cause remains obscure. They are frequently an early feature and were thought to be the initial manifestation of MS in six of the 32 patients in this series. Hyperventilation sometimes provokes attacks, even within seconds, and we have the impression that anxiety is prominent in these patients. In patients with advanced physical disability and concomitant emotional disturbances, there may be scepticism on the part of the physician regarding the organic nature of these paroxysmal disorders and the value of therapy. The double-blind comparison of carbamazepine and placebo in the subjects reported here left no uncertainty about the efficacy of the drug. While carbamazepine's side-effects may interfere with 'double blind' administration, the therapeutic response usually preceded their onset by several days, and in several instances relatively small doses of carbamazepine (100 to 200 mg daily) were useful in suppressing attacks. Benefit was often evident within 48 hours and, once treated, the paroxysms not infrequently remitted. Patients with trigeminal neuralgia, as might be expected, tolerated larger doses of carbamazepine than those with paroxysms of tingling in their limbs.
Although other anti-convulsant drugs have been effective in some cases (Matthews, 1958; Espir and Walker, 1967) these paroxysmal disorders are not regarded as epileptic and EEGs taken during bouts have not been disturbed. Furthermore, the superiority of carbamazepine over phenytoin parallels that witnessed in the management of trigeminal neuralgia (Lewis, 1969) . Kuroiwa and Shibasaki (1967) using carbamazepine and placebo in a double blind trial, also found that the drug was effective in controlling various types of tonic seizures in four patients with MS. Harrison and McGill (1969) reported a patient with paroxysmal dysarthria which responded to carbamazepine but not to phenobarbitone, primidone, or placebo. They considered that the transient attacks might have arisen from a build up of post-synaptic facilitation from a discharge around the brain-stem plaque, and that carbamazepine might suppress this phenomenon. Ekbom, Westerberg, and Osterman (1968) reported two patients with focal sensory-motor seizures of spinal origin resembling the cases we have reported. in that attacks were of brief duration, recurred frequently, and in one of their cases ceased within 24 hours when carbamazepine was administered. They assumed that these seizures were due to an irritative lesion with a transversely spreading activation of axons at the affected level in the spinal cord, thus explaining the crossed distribution of the tonic spasm and the sensory disturbances that they described. In a similar case reported by Castaigne Cambier, and Brunet (1968) carbamazepine also arrested the seizures within 24 hours and these authors agreed with the explanation given by Professor Ekbom and his colleagues.
Our experience confirms the value of carbamazepine in suppressing paroxysmal symptoms in MS and the dramatic response made by some patients with differing paroxysms suggests a common mechanism. Whatever the underlying cause, it seems likely that paroxysms result from a degree of demyelination insufficient to give persistent deficit, but rendering axons hypersensitive to minor stresses.
